Previous studies have reported that USP10 promotes cisplatin resistance by deubiquitinating HDAC6 in non-small cell lung cancer [44], and promotes tumor growth and proliferation by deubiquitinating TAZ/YAP in liver cancer [45]. Here, HDAC6 is linked to non-small cell lung carcinoma.